Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 30Carcinoma, Non-Small-Cell Lung 30Lung Neoplasms 23Head and Neck Neoplasms 21Squamous Cell Carcinoma of Head and Neck 15Lymphoma 15Gliosarcoma 15Central Nervous System Neoplasms 14Sarcoma 12Esophageal Neoplasms 12Rectal Neoplasms 10Glioma 10Leukemia 9Breast Neoplasms 9Brain Neoplasms 9Prostatic Neoplasms 8Pancreatic Neoplasms 8Lymphoma, Follicular 7Esophageal Squamous Cell Carcinoma 7Neoplasms 6Melanoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Astrocytoma 5

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bladder Urothelial Carcinoma × Radiotherapy × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡